Mylan’s price hike for its EpiPen allergy medication fueled an Internet storm this week, with consumers and U.S. legislators expressing outrage over its decision to raise the price about 400% since 2007 to as much as $500 or more. The backlash appeared tied in part to timing as U.S. children head back to school, with parents of those needing EpiPens to treat allergic reactions coming to grips with the hefty price tag.
The incident brought echoes of another drug price hike – the 2015 increase by Turing Pharmaceutical’s malaria and HIV medicine Darapim, another move that brought scrutiny by the House Oversight and Government Reform Committee of the company’s chief executive officer. Continue reading →
Drug prices have become a hot topic – and a significant source of the ongoing challenges to achieving affordable premiums and out-of-pocket costs in both Affordable Care Act exchange plans and employer-sponsored coverage. Drug costs are now the single largest health care concern of Americans across the political spectrum, according to some polls.
But it can be hard to know where to go to find out information about drug pricing and drug value (which aren’t the same thing). Continue reading →
Photo: CDC/Debora Cartagena/CDCLegislators, facing an election year, are starting to take action in an attempt to control the drug epidemic surrounding heroin and other opioid abuse.
Stories on how heroin and other opioid abuse shattering communities have been the focus of many powerful pieces in media outlets across the country. After years of inaction, Washington, D.C. ,has begun turning its attention to the issue and moving toward some possible action.
But covering the moving parts of the Department of Health and Human Services, Congress and the White House in tackling the issue is akin to tracking a moving target, all complicated by election-year politicking. What’s a reporter – especially one outside D.C. – to do? Continue reading →
Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates social media efforts of AHCJ and assists with the editing and production of association guides, programs and newsletters.
Carla K. Johnson (@CarlaKJohnson) is a medical writer at The Associated Press and has covered health and medicine since 2001. A former member of AHCJ's board of directors, she leads the Chicago AHCJ chapter.
Photo: Carla K. JohnsonCraig Garthwaite, assistant professor, Northwestern University’s Kellogg School of Management (left); Roy Guharoy, Pharm.D. vice president and chief pharmacy officer for the Resource Group at Ascension (middle); and independent journalist and AHCJ member Duncan Moore (right) spoke at the Chicago chapter event “Drug Pricing: Covering the Controversy” at Columbia College in Chicago on Feb. 23.
A blockbuster hepatitis C drug costs $84,000, straining state budgets. Martin Shkreli acquires the rights to a generic and raises its price 5,000 percent. Presidential candidates react to the public outcry, claiming they know what to do about the drug prices.
What does it all mean? Until recently, “there’s been an equilibrium in the public mind between a free market regimen of the market setting prices and what the public and payers are willing to pay,” said independent journalist Duncan Moore, “but there are indications this informal tradeoff has begun to swing out of control.” Continue reading →